EBMT 2024 | First-line tagraxofusp followed by alloSCT in BPDCN: a case study
Cristina Papayannidis
• 22 Apr 2024
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, discusses a clinical case of a young patient with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who was treated with tagraxofusp followed by allogeneic stem cell transplantation (alloSCT). The patient remained in complete remission (CR) more than 2 years after treatment, underscoring the value of tagraxofusp as a first-line treatment followed by consolidation with alloSCT in BPDCN. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Menarini Stemline: Honoraria.
